CA2634664A1 - Novel albumin-free factor viii formulations - Google Patents
Novel albumin-free factor viii formulations Download PDFInfo
- Publication number
- CA2634664A1 CA2634664A1 CA002634664A CA2634664A CA2634664A1 CA 2634664 A1 CA2634664 A1 CA 2634664A1 CA 002634664 A CA002634664 A CA 002634664A CA 2634664 A CA2634664 A CA 2634664A CA 2634664 A1 CA2634664 A1 CA 2634664A1
- Authority
- CA
- Canada
- Prior art keywords
- factor viii
- group
- nacl
- agent selected
- raffinose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Abstract
A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
Claims
1. An improved method of lyophilizing an aqueous pharmaceutical formulation containing a crystallisable bulking agent and NaCl, wherein said method comprises the steps of:
(a) freezing the aqueous pharmaceutical formulation at a temperature of less than about -35°C;
(b) annealing the pharmaceutical formulation at between about -30°C
and -19°C;
(c) lowering the temperature of the pharmaceutical formulation to less than about -50°C;
(d) annealing the pharmaceutical formulation at between about -30°C
and -39°C; and then (e) freeze-drying the pharmaceutical formulation.
(a) freezing the aqueous pharmaceutical formulation at a temperature of less than about -35°C;
(b) annealing the pharmaceutical formulation at between about -30°C
and -19°C;
(c) lowering the temperature of the pharmaceutical formulation to less than about -50°C;
(d) annealing the pharmaceutical formulation at between about -30°C
and -39°C; and then (e) freeze-drying the pharmaceutical formulation.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25527999A | 1999-02-22 | 1999-02-22 | |
US09/255,279 | 1999-02-22 | ||
US45275299A | 1999-12-01 | 1999-12-01 | |
US09/452,752 | 1999-12-01 | ||
CA2362927A CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2362927A Division CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2634664A1 true CA2634664A1 (en) | 2000-08-24 |
CA2634664C CA2634664C (en) | 2011-08-09 |
Family
ID=26944588
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002634663A Expired - Lifetime CA2634663C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
CA2634664A Expired - Lifetime CA2634664C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
CA002634674A Abandoned CA2634674A1 (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
CA2362927A Expired - Lifetime CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002634663A Expired - Lifetime CA2634663C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002634674A Abandoned CA2634674A1 (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
CA2362927A Expired - Lifetime CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Country Status (19)
Country | Link |
---|---|
US (8) | US6586573B1 (en) |
EP (5) | EP1820516B1 (en) |
JP (9) | JP5149470B2 (en) |
CN (3) | CN101810854A (en) |
AT (1) | ATE365052T1 (en) |
AU (1) | AU777972B2 (en) |
BR (1) | BR0008405B1 (en) |
CA (4) | CA2634663C (en) |
CY (2) | CY1108030T1 (en) |
CZ (3) | CZ307322B6 (en) |
DE (1) | DE60035260T2 (en) |
DK (4) | DK1154796T3 (en) |
ES (4) | ES2435141T3 (en) |
HK (4) | HK1139862A1 (en) |
MX (1) | MXPA01008515A (en) |
PL (4) | PL203177B1 (en) |
PT (4) | PT2193809E (en) |
RU (1) | RU2244556C2 (en) |
WO (1) | WO2000048635A1 (en) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
PT2193809E (en) * | 1999-02-22 | 2015-08-24 | Baxter Int | Albumin-free factor viii formulations |
US6830917B2 (en) * | 2001-12-10 | 2004-12-14 | Baxter Healthcare S.A. | Method of isolation and purification of trypsin from pronase protease and use thereof |
BR0215216A (en) | 2001-12-21 | 2004-11-16 | Novo Nordisk Healthcare Ag | Liquid aqueous composition, method for preparing a liquid aqueous composition of a factor vii polypeptide, use of a liquid aqueous composition, and method for treating a factor vii response syndrome |
KR20040065278A (en) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | Liquid composition of modified factor vii polypeptides |
US6878168B2 (en) | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US6982080B2 (en) * | 2002-03-15 | 2006-01-03 | Wyeth | Hydroxyethyl starch—containing polypeptide compositions |
GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
KR101212025B1 (en) * | 2002-06-21 | 2013-01-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Stabilised solid compositions of factor ⅶ polypeptides |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
CA2518327A1 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
AU2004241698A1 (en) * | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
ES2382157T3 (en) * | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Liquid composition of factor VII polypeptides |
ATE446768T1 (en) * | 2003-07-01 | 2009-11-15 | Novo Nordisk Healthcare Ag | LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES |
DE10333317A1 (en) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulation for protein medicines without the addition of human serum albumin (HSA) |
CA2531988C (en) * | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
KR100560697B1 (en) * | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | Formulation of albumin-free erythropoietin |
EP1656158B1 (en) | 2003-08-14 | 2016-03-09 | Novo Nordisk Health Care AG | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
US8541002B2 (en) * | 2003-09-12 | 2013-09-24 | Agenus Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
MXPA06006886A (en) * | 2003-12-19 | 2006-09-04 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor vii polypeptides. |
GB0404586D0 (en) * | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
WO2005089712A1 (en) * | 2004-03-04 | 2005-09-29 | Wyeth | Lyophilization method to improve excipient crystallization |
CA2557061C (en) * | 2004-03-19 | 2013-08-20 | Baxter International Inc. | Factor ixa for the treatment of bleeding disorders |
US7319032B2 (en) * | 2004-04-22 | 2008-01-15 | Medtox | Non-sugar sweeteners for use in test devices |
KR100624013B1 (en) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | Pharmaceutical preparation of recombinant factor ? lyophilized without albumin as a stabilizer |
PT1835938E (en) * | 2004-12-27 | 2013-11-06 | Baxter Int | Polymer-von willebrand factor-conjugates |
FR2881139A1 (en) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Liquid for lyophilization of proteins, useful for stabilizing pharmaceuticals or analytical proteins, comprises a filler, stabilizer, buffer and optionally nonionic surfactant |
US7956160B2 (en) * | 2005-07-22 | 2011-06-07 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
JP5555425B2 (en) | 2005-11-01 | 2014-07-23 | ワイス・エルエルシー | Sodium chloride solution for drug reconstitution or dilution |
EP2299271B9 (en) * | 2005-11-09 | 2014-02-26 | Ajinomoto Co., Inc. | Kokumi-imparting compositions |
US8420144B2 (en) * | 2005-11-09 | 2013-04-16 | Ajinomoto Co., Inc. | Kokumi-imparting agent, method of using, and compositions containing same |
WO2007055388A2 (en) * | 2005-11-09 | 2007-05-18 | Ajinomoto Co., Inc. | Calcium receptor activator |
RU2008118166A (en) * | 2005-11-22 | 2009-12-27 | Вайет (Us) | COMPOSITIONS CONTAINING HYBRID PROTEINS INCLUDING IMMUNOGLOBULIN |
PT1969004E (en) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
JP5094850B2 (en) * | 2006-05-31 | 2012-12-12 | ジェンザイム コーポレーション | Use of polysaccharides to promote enzyme activity |
CN103933612B (en) | 2006-10-27 | 2016-06-22 | 爱德华兹生命科学公司 | Biological tissue for Srgery grafting |
AR063606A1 (en) * | 2006-11-07 | 2009-02-04 | Acambis Inc | VACCINE STABILIZATION THROUGH LIOFILIZATION |
JP5876208B2 (en) | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Factor VIIa- (poly) sialic acid conjugate with extended in vivo half-life |
FR2913020B1 (en) | 2007-02-23 | 2012-11-23 | Biomethodes | NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS |
WO2008107908A1 (en) * | 2007-03-05 | 2008-09-12 | Cadila Healthcare Limited | Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant |
AU2013204652B2 (en) * | 2007-04-26 | 2015-06-18 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
RU2469739C2 (en) * | 2007-04-26 | 2012-12-20 | БАЙЕР ХЕЛСКЕА ЛЛСи | Stabilisation of liquid solutions of recombinant protein for storing in frozen state |
EP2156753A4 (en) * | 2007-05-08 | 2010-11-24 | Ajinomoto Kk | Low-fat food |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
US9034818B2 (en) * | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
CN101376022B (en) * | 2007-08-31 | 2011-11-30 | 上海医药工业研究院 | Medicament composition containing defibrase modified by PEG |
CA2991162A1 (en) * | 2007-12-21 | 2009-07-02 | Aptevo Biotherapeutics Llc | Stabilized factor ix formulations containing trehalose |
US8357387B2 (en) | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
SG10201503304RA (en) * | 2007-12-27 | 2015-06-29 | Baxter Int | Cell culture processes |
EP2113564A1 (en) * | 2008-05-01 | 2009-11-04 | Arecor Limited | Protein formulation |
CA2729972C (en) * | 2008-08-05 | 2018-11-20 | Wyeth Llc | Lyophilization above collapse |
AU2009284113B2 (en) | 2008-08-21 | 2015-05-14 | Octapharma Ag | Recombinantly produced human factor VIII and IX |
MX2011002159A (en) * | 2008-08-27 | 2011-03-29 | Schering Corp | Lyophilized formulatons of engineered anti-il-23p19 antibodies. |
EP2337580B1 (en) * | 2008-09-03 | 2012-03-28 | Octapharma AG | Stabilized compositions for recombinantly produced factor viii |
US20100068210A1 (en) * | 2008-09-10 | 2010-03-18 | Ji Junyan A | Compositions and methods for the prevention of oxidative degradation of proteins |
AU2009309623B9 (en) * | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
BRPI0921429B1 (en) | 2008-11-07 | 2022-07-12 | Takeda Pharmaceutical Company Limited | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION, AND METHOD FOR PREPARING A STABLE LYOPHILIZED FACTOR |
EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
DK2459224T3 (en) | 2009-07-27 | 2016-07-25 | Baxalta GmbH | Blodstørkningsproteinkonjugater |
ES2856055T3 (en) | 2009-07-27 | 2021-09-27 | Baxalta GmbH | Glycopolysialylation of proteins other than blood clotting proteins |
GB0915480D0 (en) | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
ES2865250T3 (en) | 2009-09-21 | 2021-10-15 | Takeda Pharmaceuticals Co | Stabilized Liquid and Freeze-Dried ADAMTS13 Formulations |
EP2496246B1 (en) | 2009-11-03 | 2018-06-27 | Grifols Therapeutics LLC | Composition, method, and kit for alpha-1 proteinase inhibitor |
HUE037733T2 (en) * | 2009-11-24 | 2018-09-28 | Grifols Therapeutics Inc | Lyophilization methods, compositions, and kits |
RU2012135505A (en) * | 2010-01-19 | 2014-02-27 | Ханми Сайенс Ко., Лтд. | LIQUID COMPOSITIONS FOR LONG-TERM ETHYTROPOETIN CONJUGATE |
EP2549957B1 (en) | 2010-03-23 | 2019-01-30 | Edwards Lifesciences Corporation | Methods of conditioning sheet bioprosthetic tissue |
US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
TW201213342A (en) * | 2010-09-17 | 2012-04-01 | Baxter Int | Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral pH |
US9173944B2 (en) | 2010-10-12 | 2015-11-03 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
JP6049625B2 (en) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー/エス | Treatment of diabetes mellitus using insulin injections given at various injection intervals |
EA035447B1 (en) | 2010-11-05 | 2020-06-17 | Баксалта Инкорпорейтид | Isolated recombinant partially b-domain deleted factor viii (fviii) variant |
US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
WO2012079979A1 (en) * | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Aqueous factor viii solution |
PL2654794T3 (en) | 2010-12-22 | 2020-07-27 | Baxalta GmbH | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
BRPI1105317A2 (en) | 2011-01-24 | 2013-04-30 | Fundacco Hemoct De Ribeirco Preto | stable and large-scale production of human fviii in human cell line sk-hep-1 |
KR102289394B1 (en) | 2011-03-31 | 2021-08-13 | 머크 샤프 앤드 돔 코포레이션 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
JP6060447B2 (en) | 2011-04-08 | 2017-01-18 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | Sso7 polymerase conjugate with reduced non-specific activity |
CN103703141B (en) | 2011-04-08 | 2016-08-17 | 伯乐实验室公司 | There is the PCR reactant mixture of the nonspecific activity of reduction |
US20140227250A1 (en) | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
CN105209487A (en) * | 2013-03-15 | 2015-12-30 | 拜耳医药保健有限公司 | Recombinant Factor VIII formulations |
CA2899737A1 (en) * | 2013-03-15 | 2014-09-18 | Biogen Ma Inc. | Factor viii polypeptide formulations |
US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
KR102058864B1 (en) * | 2013-12-16 | 2019-12-24 | 주식회사 티움바이오 | Pharmaceutical composition having improved stability comprising a fusion protein of factor vii |
MX2016012870A (en) * | 2014-04-01 | 2017-05-12 | Advantech Bioscience Farmacêutica Ltda | Stable factor viii formulations with low sugar-glycine. |
US9855319B2 (en) | 2014-04-01 | 2018-01-02 | Advantech Bioscience Farmacêutica Ltda | Stabilization of factor VIII without calcium as an excipient |
AU2015299224B2 (en) * | 2014-08-04 | 2019-06-20 | Csl Limited | Factor VIII formulation |
CA2961739A1 (en) * | 2014-08-20 | 2016-02-25 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
CN114129709A (en) * | 2014-10-23 | 2022-03-04 | 恩格姆生物制药公司 | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
DK3287140T3 (en) | 2015-04-21 | 2021-07-19 | Beijing Staidson Medical Tech Co Ltd | Nerve growth factor composition and powder injection |
US10576129B2 (en) | 2015-04-21 | 2020-03-03 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Nerve growth factor composition and powder injection |
US20170007694A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilization of proteins |
GB2556002B (en) | 2015-07-07 | 2020-12-16 | Bluewillow Biologics Inc | Methods and compositions for nanoemulsion vaccine formulations |
WO2017011275A1 (en) * | 2015-07-10 | 2017-01-19 | Nersissian Aram M | Factor viii protein compositions and methods of treating hemophilia a |
EP3167877A1 (en) * | 2015-11-12 | 2017-05-17 | Bayer Pharma Aktiengesellschaft | Method for the production of freeze-dried pellets comprising factor viii |
US20190046450A1 (en) * | 2016-02-24 | 2019-02-14 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
CN109640961B (en) * | 2016-06-01 | 2021-11-02 | 施维雅知识产权英国有限公司 | Polyalkylene oxide-asparaginase formulations and methods of making and using same |
CN110381962B (en) * | 2016-12-21 | 2023-10-13 | 孙崇谨 | Novel method for the active preservation of plasma proteins |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JP6630315B2 (en) | 2017-06-27 | 2020-01-15 | 矢崎総業株式会社 | Noise reduction unit |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
AU2020204922A1 (en) * | 2019-01-06 | 2021-07-01 | Endo Global Aesthetics Limited | Collagenase formulations and methods of producing the same |
EP3994162A1 (en) | 2019-07-04 | 2022-05-11 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
CN110772487B (en) * | 2019-12-09 | 2021-09-21 | 湖南科伦制药有限公司 | Freeze-drying method of ethylenediamine diaceturate |
CN112121009B (en) * | 2020-09-24 | 2022-12-02 | 科兴生物制药股份有限公司 | New preparation of polyethylene glycol modified recombinant human granulocyte stimulating factor |
EP4217394A1 (en) | 2020-09-24 | 2023-08-02 | Merck Sharp & Dohme LLC | Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof |
EP4240757A2 (en) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
WO2022217041A1 (en) * | 2021-04-09 | 2022-10-13 | Hyalo Technologies, LLC | Method of sterilization of biologics |
AU2022326188A1 (en) * | 2021-08-11 | 2024-02-22 | Grifols Worldwide Operations Limited | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained |
CN114015758B (en) * | 2021-10-15 | 2022-06-24 | 无锡百泰克生物技术有限公司 | Freeze-drying protective agent, fluorescent PCR detection kit and freeze-drying process |
Family Cites Families (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB941019A (en) | 1961-04-27 | 1963-11-06 | Crookes Lab Ltd | Improvements in and relating to the stability of anti-haemophilic globulin (factor viii) |
US3389314A (en) | 1962-05-07 | 1968-06-18 | Penn Controls | Proportional silicon controlled rectifier driven system for a heat motor |
US3681126A (en) | 1969-11-25 | 1972-08-01 | Monsanto Co | Flame retardant article containing tris-(3 - halo - 2-hydroxypropyl)-hydroxymethylphosphonium chloride |
US3839314A (en) | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US3770631A (en) | 1971-06-29 | 1973-11-06 | Baxter Laboratories Inc | Clarification of blood serum and plasma |
US4073886A (en) | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
US3980432A (en) | 1973-04-02 | 1976-09-14 | Behringwerke Aktiengesellschaft | Partial thromboplastin, its use as diagnostic agent and process for preparing it |
US3893990A (en) | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene |
US3893991A (en) | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4189425A (en) | 1975-04-11 | 1980-02-19 | Edward Shanbrom, Inc. | Method of preserving blood plasma I |
US4086218A (en) | 1975-04-11 | 1978-04-25 | Edward Shanbrom, Inc. | Method of preserving blood plasma II |
US4069216A (en) | 1975-06-16 | 1978-01-17 | Edward Shanbrom, Inc. | Simplified methods for preparation of very high purity Factor VIII concentrate |
US4089944A (en) | 1975-12-22 | 1978-05-16 | Baxter Travenol Laboratories, Inc. | Rapidly solubilized AHF composition and process for preparing same |
US4027013A (en) | 1976-01-22 | 1977-05-31 | William L. Wilson | Clottable fibrinogen free factor VIII and albumin product and process |
SU663404A1 (en) | 1976-12-30 | 1979-05-25 | Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им. М.В.Ломоносова | Method of obtaining fibrin monomer |
US4137223A (en) | 1977-05-16 | 1979-01-30 | Edward Shanbrom, Inc. | Method of preserving blood plasma II |
SE443293B (en) | 1978-01-25 | 1986-02-24 | Blombaeck E G B | Blood fraction FRONT TELL NING |
DE2916711A1 (en) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blood coagulation factors and process for their manufacture |
US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
FR2460305A2 (en) | 1979-06-29 | 1981-01-23 | Merieux Inst | PROCESS FOR PREPARING A FACTOR VIII CONCENTRATE |
US4386068A (en) | 1980-02-26 | 1983-05-31 | Cutter Laboratories, Inc. | Antihemophilic factor concentrate and method for preparation |
US4623717A (en) | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4341764A (en) | 1980-03-05 | 1982-07-27 | Cutter Laboratories, Inc. | Method of preparing fibronectin and antihemophilic factor |
DE3176491D1 (en) | 1980-03-05 | 1987-11-26 | Miles Lab | Pasteurized therapeutically active protein compositions |
US4440679A (en) | 1980-03-05 | 1984-04-03 | Cutter Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
JPS56127308A (en) | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical |
JPS56135418A (en) | 1980-03-27 | 1981-10-22 | Green Cross Corp:The | Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human |
AT369263B (en) | 1980-08-27 | 1982-12-27 | Immuno Ag | METHOD FOR PRODUCING A FACTOR VIII (AHF) HIGH CONCENTRATE |
DE3033932C2 (en) | 1980-09-10 | 1984-05-24 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Process for the cold sterilization of preparations containing blood coagulation factor VIII |
JPS5770814A (en) | 1980-10-17 | 1982-05-01 | Isamu Horikoshi | Oral preparation of blood clotting eighth factor |
US4495278A (en) | 1981-04-27 | 1985-01-22 | Baxter Travenol Laboratories, Inc. | Process for making novel blood clotting enzyme compositions |
US4382083A (en) | 1981-06-25 | 1983-05-03 | Baxter Travenol Laboratories, Inc. | Therapeutic method for treating blood-clotting defects with factor VIIa |
US4479938A (en) | 1981-06-25 | 1984-10-30 | Baxter Travenol Laboratories, Inc. | Therapeutic composition containing factor VIIa |
JPS5874617A (en) | 1981-10-28 | 1983-05-06 | Green Cross Corp:The | Heat-treating method of aqueous solution containing blood coagulation factor 8 derived from human |
US4456590B2 (en) | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
US4481189A (en) | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
US4591505A (en) | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
US4495175A (en) | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
DE3230849A1 (en) | 1982-08-19 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | PASTEURIZED HUMAN FIBRINOGEN (HF) AND METHOD FOR THE PRODUCTION THEREOF |
DE3237512A1 (en) | 1982-10-09 | 1984-04-12 | Behringwerke Ag, 3550 Marburg | METHOD FOR PASTEURIZING ANTIHAEMOPHILIC CRYOPRAEZIPITATE (AHK) AND ANTIHAEMOPHILE CRYOPRAECIPITATE PRODUCED THEREOF |
GB2129685B (en) | 1982-11-11 | 1985-11-13 | Nat Biolog Standards Board | Anti-haemophilic compositions |
JPS59134730A (en) | 1983-01-20 | 1984-08-02 | Green Cross Corp:The | Heat treatment of viii factor of blood clotting |
ZA842418B (en) | 1983-03-31 | 1984-11-28 | Scripps Clinic Res | Factor viii coagulant polypeptides and monoclonal antibodies to them |
US4748120A (en) | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4727027A (en) | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
DE3481109D1 (en) | 1983-05-09 | 1990-03-01 | Novo Nordisk As | ANTIHAEMOPHILIA FACTOR VIII CONCENTRATE AND THEIR PRODUCTION METHOD. |
AT379510B (en) | 1983-05-20 | 1986-01-27 | Immuno Ag | METHOD FOR PRODUCING A FACTOR VIII (AHF) CONTAINING PRAEPARATION |
DE3318521A1 (en) | 1983-05-20 | 1984-11-22 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | METHOD FOR PRODUCING AN ANTIHAEMOPHILIE FACTOR CONCENTRATE |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
DE3336631A1 (en) | 1983-10-08 | 1985-04-18 | Behringwerke Ag, 3550 Marburg | METHOD FOR THE PASTEURIZATION OF PLASMA OR CONCENTRATES OF THE BLOOD COAGINING FACTORS II, VII, IX AND X |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4693981A (en) | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
JPS6122022A (en) | 1983-12-28 | 1986-01-30 | Green Cross Corp:The | Method for heat-treating blood plasma protein |
DE10399009I1 (en) | 1984-01-12 | 2003-10-23 | Chiron Corp | DNA sequences encoding factor VIIIc and related DNA constructions |
AT389815B (en) | 1984-03-09 | 1990-02-12 | Immuno Ag | METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASERS IN BLOOD PRODUCTS |
US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
JPS60199829A (en) | 1984-03-24 | 1985-10-09 | Nippon Sekijiyuujishiya | Preparation of high-purity antihemophilic globulin |
US5043428A (en) | 1984-08-31 | 1991-08-27 | Behringwerke Aktiengesellschaft | Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production |
US4543210A (en) | 1984-10-04 | 1985-09-24 | Miles Laboratories, Inc. | Process for producing a high purity antihemophilic factor concentrate |
US4613501A (en) | 1984-12-21 | 1986-09-23 | New York Blood Center, Inc. | Inactivation of viruses in labile blood derivatives |
JPS61271222A (en) * | 1985-05-24 | 1986-12-01 | Dainippon Pharmaceut Co Ltd | Human interleukine 1 polypeptide and derivative thereof |
US4952675A (en) | 1985-02-01 | 1990-08-28 | New York University | Method for purifying antihemophilic factor |
US4847362A (en) | 1985-02-01 | 1989-07-11 | New York University | Method for purifying antihemophilic factor |
US4743680A (en) | 1985-02-01 | 1988-05-10 | New York University | Method for purifying antihemophilic factor |
EP0218712B1 (en) | 1985-04-12 | 1992-02-26 | Genetics Institute, Inc. | Novel procoagulant proteins |
US4891319A (en) | 1985-07-09 | 1990-01-02 | Quadrant Bioresources Limited | Protection of proteins and the like |
US4758657A (en) | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
EP0212040B1 (en) | 1985-08-05 | 1990-05-23 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Process for producing preparations based on blood coagulation factors |
AU6487286A (en) | 1985-11-08 | 1987-05-14 | Baxter Travenol Laboratories Inc. | Antihemophilic factor by cold precipitation |
US5180583A (en) | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
JPS62195331A (en) | 1986-02-24 | 1987-08-28 | Nippon Sekijiyuujishiya | Production of blood coagulation factor viii pharmaceutical |
AT390374B (en) | 1986-03-18 | 1990-04-25 | Schwab & Co Gmbh | METHOD FOR PASTEURIZING PLASMA PROTEIN AND PLASMA PROTEIN FRACTIONS |
DE3609431A1 (en) | 1986-03-20 | 1987-09-24 | Biotest Pharma Gmbh | METHOD FOR PRODUCING A STERILE PRESERVATIVE CONTAINING THE BLOOD coagulation factor VIII |
US4841023A (en) | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
AT391808B (en) | 1986-11-03 | 1990-12-10 | Immuno Ag | METHOD FOR PRODUCING A FACTOR VIII (AHF) CONTAINING FRACTION |
GB8628104D0 (en) | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
ES2006632A6 (en) | 1987-04-21 | 1989-05-01 | Green Cross Corp | Process for heat treating fibrinogen |
US4876241A (en) | 1987-05-22 | 1989-10-24 | Armour Pharmaceutical Company | Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants |
IL86417A (en) | 1987-05-22 | 1992-09-06 | Armour Pharma | Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers |
US4795806A (en) | 1987-07-16 | 1989-01-03 | Miles Laboratories, Inc. | Phospholipid affinity purification of Factor VIII:C |
JPH0387173A (en) | 1987-09-10 | 1991-04-11 | Teijin Ltd | Preparation of human active natural type factor viii c and transformant using the same |
DE3730533A1 (en) | 1987-09-11 | 1989-03-30 | Biotest Pharma Gmbh | METHOD FOR STERILIZING PLASMA OR PLASMA FACTIONS |
KR890004724A (en) * | 1987-09-17 | 1989-05-09 | 히사시 미하라 | New protease preparations |
CA1329760C (en) | 1987-10-29 | 1994-05-24 | Ted C. K. Lee | Plasma and recombinant protein formulations in high ionic strength media |
US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
US5177191A (en) | 1987-12-21 | 1993-01-05 | Miles, Inc. | Gel filtration of factor VIII |
DK18288D0 (en) | 1988-01-15 | 1988-01-15 | Nordisk Gentofte | PROCEDURE FOR PASTEURIZATION OF Aqueous SOLUTIONS OF FACTOR VIII |
WO1989009784A1 (en) | 1988-04-08 | 1989-10-19 | Commonwealth Serum Laboratories Commission | Production of heat-stable factor viii concentrate |
US4981951A (en) | 1988-04-14 | 1991-01-01 | Miles Inc. | Lectin affinity chromatography of factor VIII |
FR2632309B1 (en) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | PROCESS FOR THE CHROMATOGRAPHIC PURIFICATION OF PROTEINS, PARTICULARLY FACTOR VIII, AND THE PRODUCTS OBTAINED |
US5047249A (en) | 1988-07-22 | 1991-09-10 | John Morris Co., Inc. | Compositions and methods for treating skin conditions and promoting wound healing |
US5051353A (en) | 1988-08-09 | 1991-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Preservation and restoration of hemoglobin in blood substitutes |
JPH02157231A (en) * | 1988-12-07 | 1990-06-18 | Bio Kagaku Kenkyusho:Kk | Cytostatic agent |
DE3904354A1 (en) | 1989-02-14 | 1990-08-16 | Behringwerke Ag | PASTEURIZED, PURIFIED OF WILLEBRAND FACTOR CONCENTRATE AND METHOD FOR THE PRODUCTION THEREOF |
FR2665449B1 (en) | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | METHOD FOR MANUFACTURING A VON WILLEBRAND FACTOR HAVING VERY HIGH PURITY, MAINLY LACKING AN ANTIHEMOPHILIC FACTOR (FVIIIC), AND VON WILLEBRAND FACTOR THUS OBTAINED, AS WELL AS A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME. |
US5760183A (en) | 1989-02-17 | 1998-06-02 | Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques | Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same |
CN1047342A (en) | 1989-05-13 | 1990-11-28 | 杭州市中心血站 | The production of Factor IX and virus inactivating method thereof |
DK0399321T3 (en) | 1989-05-24 | 1993-08-09 | Miles Inc | Gel filtration of heat treated factor VIII |
GB8913183D0 (en) * | 1989-06-08 | 1989-07-26 | Central Blood Lab Authority | Chemical products |
US5138034A (en) | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
US5062498A (en) | 1989-07-18 | 1991-11-05 | Jaromir Tobias | Hydrostatic power transfer system with isolating accumulator |
DK0410207T3 (en) | 1989-07-24 | 1997-07-14 | Bayer Ag | Stabilization of Highly Purified Proteins. |
DE3926034C3 (en) | 1989-08-07 | 1996-11-21 | Behringwerke Ag | Process for the preparation of a stable factor VIII |
FR2651437A1 (en) | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | PROCESS FOR PREPARING A CONCENTRATE OF THE VON WILLEBRAND FACTOR VIII-FACTOR COMPLEX OF BLOOD COAGULATION FROM TOTAL PLASMA. |
DK162233C (en) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | PROCEDURE FOR INSULATING FACTOR VIII FROM BLOOD PLASMA AND PHARMACEUTICAL PREPARATION CONTAINING THE ASSOCIATED PHATAR VIII |
SE465222C5 (en) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | A recombinant human factor VIII derivative and process for its preparation |
US5439882A (en) | 1989-12-29 | 1995-08-08 | Texas Tech University Health Sciences Center | Blood substitute |
DE4001451A1 (en) | 1990-01-19 | 1991-08-01 | Octapharma Ag | STABLE INJECTABLE SOLUTIONS OF FACTOR VIII AND FACTOR IX |
US5587490A (en) | 1990-04-16 | 1996-12-24 | Credit Managers Association Of California | Method of inactivation of viral and bacterial blood contaminants |
US5418130A (en) | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
US5798238A (en) | 1990-04-16 | 1998-08-25 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer |
WO1991017194A1 (en) * | 1990-05-07 | 1991-11-14 | Exxon Chemical Patents Inc. | UNSATURATED α-OLEFIN COPOLYMERS AND METHOD FOR PREPARATION THEREOF |
US5378612A (en) | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
US5712086A (en) | 1990-05-15 | 1998-01-27 | New York Blood Center, Inc. | Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions |
US5232844A (en) | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
FR2662166A1 (en) | 1990-05-18 | 1991-11-22 | Fondation Nale Transfusion San | PROCESS FOR PREPARING HIGHLY HIGH PURITY FACTOR VIII COMPRISING A RAPID IMMUNOADSORPTION STEP |
IT1248723B (en) | 1990-06-12 | 1995-01-26 | Scalvo S P A | PROCESS FOR THE PURIFICATION OF FACTOR VIII AND FACTOR VIII OBTAINED WITH SUCH PROCESS |
JP3127263B2 (en) | 1990-07-12 | 2001-01-22 | バクスター、ダイアグノスティックス、インコーポレイテッド | Part VIII: Ca factor chromogen assay |
AU650045B2 (en) | 1990-09-12 | 1994-06-09 | Lifecell Corporation | Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
FR2673632A1 (en) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE |
DE4111393A1 (en) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | STABILIZED FACTOR VIII PREPARATIONS |
SE468480B (en) | 1991-05-24 | 1993-01-25 | Arne Holmgren | Modified thioredoxin and its use |
AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
US5254350A (en) | 1991-07-22 | 1993-10-19 | Helena Laboratories Corporation | Method of preparing a thromboplastin extract |
CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
FR2681867B1 (en) | 1991-09-26 | 1993-12-31 | Pasteur Merieux Serums Vaccins | FACTOR VIII PURIFICATION PROCESS AND PREPARATIONS OBTAINED. |
US5278289A (en) | 1991-11-12 | 1994-01-11 | Johnson Alan J | Antihemophilic factor stabilization |
US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
JPH05331071A (en) * | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | Lyophilized composition of calcitonin gene-related peptide and stabilization thereof |
AT399818B (en) | 1992-04-24 | 1995-07-25 | Immuno Ag | METHOD FOR PRODUCING A HIGH PURIFIED VIRUS-SAFE FACTOR VIII PREPARATION |
EP0638091B1 (en) | 1992-04-30 | 2005-12-07 | Probitas Pharma Inc. | Improved solubilization and stabilization of factor viii complex |
US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
US5378601A (en) | 1992-07-24 | 1995-01-03 | Montefiore Medical Center | Method of preserving platelets with apyrase and an antioxidant |
US5424471A (en) * | 1992-07-31 | 1995-06-13 | U.S. Bioscience, Inc. | Crystalline amifostine compositions and methods of the preparation and use of same |
EP1652534A3 (en) * | 1992-10-02 | 2007-05-02 | Genetics Institute, LLC | Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer |
IT1256622B (en) | 1992-12-04 | 1995-12-12 | Sclavo Spa | PROCESS FOR THE EXTRACTION OF THE FACTOR VIII-FACTOR VON WILLEBRAND (FVIII: C-FVW) FROM TOTAL HUMAN PLASMA. |
DE4242863A1 (en) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stable lyophilized pharmaceutical preparations of G-CSF |
WO1994017834A1 (en) | 1993-02-09 | 1994-08-18 | Octapharma Ag | Method for inactivating viruses devoid of lipid envelopes |
SE9301581D0 (en) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | PROTEIN FORMULATION |
SE504074C2 (en) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Protein preparation for subcutaneous, intramuscular or intradermal administration |
US5576291A (en) | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
US5353835A (en) | 1993-09-23 | 1994-10-11 | Ingersoll-Rand Company | Air tank drain |
IT1268920B1 (en) | 1994-03-29 | 1997-03-13 | Syfal Srl | ROTARY MACHINE FOR DECORATION-GLAZING IN PARTICULAR CERAMIC TILES. |
IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
US5514781A (en) | 1994-04-11 | 1996-05-07 | Bayer Corporation | Use of azoles as virucidal agents in solutions of biologically active proteins |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
FR2719479B1 (en) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Stable lyophilized formulation comprising a protein: assay kit. |
DE69530196T2 (en) | 1994-06-02 | 2003-11-20 | Elan Drug Delivery Ltd | METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
DE4431833C1 (en) | 1994-09-07 | 1995-05-18 | Blutspendedienst Der Drk Lande | Prepn. of an anti-haemophilic factor from a cryo-precipitate |
GB2293100A (en) | 1994-09-15 | 1996-03-20 | Medeva Europ Ltd | Pharmaceutical compositions with deuterium oxide |
SE9403915D0 (en) | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
SE503424C2 (en) | 1994-11-14 | 1996-06-10 | Pharmacia Ab | Process for purification of recombinant coagulation factor VIII |
AU4526996A (en) * | 1994-12-28 | 1996-07-19 | Biotime, Inc. | Plasma expanders and blood substitutes |
GB9501040D0 (en) | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
SE9501189D0 (en) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
US5679549A (en) | 1995-05-04 | 1997-10-21 | Bayer Corporation | Production of recombinant factor VIII in the presence of liposome-like substances of mixed composition |
JP3927248B2 (en) * | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | HGF lyophilized formulation |
KR0167677B1 (en) * | 1995-08-31 | 1999-02-01 | 김광호 | Memory test system with pattern generator for multi-bit test |
SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
ES2099678B1 (en) | 1995-11-03 | 1998-02-16 | Grifols Grupo Sa | PROCEDURE FOR THE INACTIVATION OF VIRUSES IN PROTEINS. |
ATE235814T1 (en) | 1995-11-06 | 2003-04-15 | New York Blood Ct Inc | TREATMENT OF RED BLOOD CELLS TO INACTIVATE VIRIA BY USING PATHALOCYANINS AND RED LIGHT |
US5659017A (en) | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
US5925738A (en) | 1995-12-01 | 1999-07-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
PT2193809E (en) * | 1999-02-22 | 2015-08-24 | Baxter Int | Albumin-free factor viii formulations |
JP4674021B2 (en) | 1999-07-13 | 2011-04-20 | ビオヴィトルム・アクチボラゲット(プブリクト) | Stable factor VIII composition |
US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
MXPA06006886A (en) | 2003-12-19 | 2006-09-04 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor vii polypeptides. |
EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | Antibody-containing stabilizing preparation |
JO3324B1 (en) | 2006-04-21 | 2019-03-13 | Amgen Inc | Lyophilized Therapeutic Peptibody Formulations |
EP2337580B1 (en) | 2008-09-03 | 2012-03-28 | Octapharma AG | Stabilized compositions for recombinantly produced factor viii |
-
2000
- 2000-02-22 PT PT100750199T patent/PT2193809E/en unknown
- 2000-02-22 EP EP06077229.0A patent/EP1820516B1/en not_active Expired - Lifetime
- 2000-02-22 CZ CZ2008-827A patent/CZ307322B6/en not_active IP Right Cessation
- 2000-02-22 EP EP10075019.9A patent/EP2193809B1/en not_active Expired - Lifetime
- 2000-02-22 CN CN200910171121A patent/CN101810854A/en active Pending
- 2000-02-22 DK DK00907322T patent/DK1154796T3/en active
- 2000-02-22 US US09/507,011 patent/US6586573B1/en not_active Expired - Lifetime
- 2000-02-22 RU RU2001125929/15A patent/RU2244556C2/en active
- 2000-02-22 PT PT09075396T patent/PT2130554E/en unknown
- 2000-02-22 PL PL382288A patent/PL203177B1/en unknown
- 2000-02-22 EP EP15154020.0A patent/EP2921180B1/en not_active Expired - Lifetime
- 2000-02-22 DK DK06077229.0T patent/DK1820516T3/en active
- 2000-02-22 ES ES06077229T patent/ES2435141T3/en not_active Expired - Lifetime
- 2000-02-22 ES ES10075019.9T patent/ES2541470T3/en not_active Expired - Lifetime
- 2000-02-22 WO PCT/US2000/040068 patent/WO2000048635A1/en active Application Filing
- 2000-02-22 CN CNB008063044A patent/CN100553678C/en not_active Expired - Lifetime
- 2000-02-22 PL PL356453A patent/PL198123B1/en unknown
- 2000-02-22 DK DK10075019.9T patent/DK2193809T3/en active
- 2000-02-22 CA CA002634663A patent/CA2634663C/en not_active Expired - Lifetime
- 2000-02-22 CA CA2634664A patent/CA2634664C/en not_active Expired - Lifetime
- 2000-02-22 BR BRPI0008405-0B1A patent/BR0008405B1/en not_active IP Right Cessation
- 2000-02-22 PT PT00907322T patent/PT1154796E/en unknown
- 2000-02-22 CZ CZ20012996A patent/CZ300547B6/en not_active IP Right Cessation
- 2000-02-22 AU AU28843/00A patent/AU777972B2/en not_active Expired
- 2000-02-22 MX MXPA01008515A patent/MXPA01008515A/en active IP Right Grant
- 2000-02-22 ES ES00907322T patent/ES2288843T3/en not_active Expired - Lifetime
- 2000-02-22 CN CN2009101711245A patent/CN101683522B/en not_active Expired - Lifetime
- 2000-02-22 CA CA002634674A patent/CA2634674A1/en not_active Abandoned
- 2000-02-22 EP EP09075396A patent/EP2130554B1/en not_active Revoked
- 2000-02-22 AT AT00907322T patent/ATE365052T1/en active
- 2000-02-22 PL PL382299A patent/PL203893B1/en unknown
- 2000-02-22 CA CA2362927A patent/CA2362927C/en not_active Expired - Lifetime
- 2000-02-22 JP JP2000599425A patent/JP5149470B2/en not_active Expired - Lifetime
- 2000-02-22 PL PL382300A patent/PL204701B1/en unknown
- 2000-02-22 DE DE60035260T patent/DE60035260T2/en not_active Expired - Lifetime
- 2000-02-22 PT PT60772290T patent/PT1820516E/en unknown
- 2000-02-22 DK DK09075396.3T patent/DK2130554T3/en active
- 2000-02-22 CZ CZ2008-828A patent/CZ307715B6/en not_active IP Right Cessation
- 2000-02-22 ES ES09075396T patent/ES2394755T3/en not_active Expired - Lifetime
- 2000-02-22 EP EP00907322A patent/EP1154796B1/en not_active Expired - Lifetime
-
2003
- 2003-07-01 US US10/610,723 patent/US7087723B2/en not_active Expired - Lifetime
-
2006
- 2006-05-15 US US11/434,634 patent/US7247707B2/en not_active Expired - Lifetime
-
2007
- 2007-06-18 US US11/764,770 patent/US8058226B2/en not_active Expired - Lifetime
- 2007-08-07 CY CY20071101050T patent/CY1108030T1/en unknown
- 2007-12-07 HK HK10106491.9A patent/HK1139862A1/en not_active IP Right Cessation
- 2007-12-07 HK HK07113386.8A patent/HK1106705A1/en not_active IP Right Cessation
- 2007-12-07 HK HK10100752.6A patent/HK1133583A1/en not_active IP Right Cessation
-
2008
- 2008-05-01 JP JP2008120035A patent/JP5006832B2/en not_active Expired - Lifetime
- 2008-09-30 JP JP2008255510A patent/JP5140539B2/en not_active Expired - Lifetime
-
2011
- 2011-09-30 US US13/250,789 patent/US8372800B2/en not_active Expired - Lifetime
-
2012
- 2012-01-20 JP JP2012009767A patent/JP5596064B2/en not_active Expired - Lifetime
- 2012-12-04 CY CY20121101185T patent/CY1113969T1/en unknown
-
2013
- 2013-02-06 US US13/760,900 patent/US8765665B2/en not_active Expired - Lifetime
- 2013-11-01 JP JP2013227977A patent/JP6038003B2/en not_active Expired - Lifetime
-
2014
- 2014-05-23 US US14/286,391 patent/US9352027B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 JP JP2015031316A patent/JP6155442B2/en not_active Expired - Lifetime
- 2015-11-11 JP JP2015220875A patent/JP6253627B2/en not_active Expired - Lifetime
-
2016
- 2016-02-18 HK HK16101857.2A patent/HK1213801A1/en unknown
- 2016-05-04 US US15/146,835 patent/US9669076B2/en not_active Expired - Lifetime
-
2017
- 2017-04-27 JP JP2017088289A patent/JP2017125076A/en not_active Withdrawn
-
2018
- 2018-07-02 JP JP2018125917A patent/JP2018172413A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2634664A1 (en) | Novel albumin-free factor viii formulations | |
RU2001125929A (en) | NEW Albumin-Free Formulations of Factor VIII | |
JP2002522468A5 (en) | ||
AU5103200A (en) | Freeze dried hgf preparations | |
CA2001552C (en) | Cyclophosphamide - sodium bicarbonate lyophilizates | |
US5268368A (en) | Cyclophosphamide--amino acid lyophilizates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200224 |